Teladoc Health (TDOC) Projected to Release Quarterly Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is anticipated to post its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Teladoc Health to post earnings of ($0.2171) per share and revenue of $588.45 million for the quarter. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to analysts’ expectations of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. On average, analysts expect Teladoc Health to post ($0.92) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

Teladoc Health Trading Up 0.4%

Shares of TDOC opened at $6.37 on Monday. The firm’s fifty day simple moving average is $6.15 and its two-hundred day simple moving average is $6.92. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The stock has a market capitalization of $1.16 billion, a P/E ratio of -6.43 and a beta of 2.14.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Citigroup dropped their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Canaccord Genuity Group decreased their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Finally, Bank of America lifted their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.54.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the sale, the chief executive officer directly owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.70% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.